{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:05:48Z","timestamp":1788879948663,"version":"build-2803163510"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fk0210072, JP20fk0210064, JP20fk0210056"],"award-info":[{"award-number":["JP20fk0210072, JP20fk0210064, JP20fk0210056"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fk0310101, JP20fk0210047, JP20fk0210048,"],"award-info":[{"award-number":["JP20fk0310101, JP20fk0210047, JP20fk0210048,"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fk0210058, JP20fk0210066, and JP20fk0210067"],"award-info":[{"award-number":["JP20fk0210058, JP20fk0210066, and JP20fk0210067"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>For long-term treatment of hepatitis B virus (HBV) infection, switching from tenofovir-disoproxil-fumarate (TDF) to tenofovir-alafenamide (TAF) may prevent renal dysfunction and bone loss. However, the precise effects of this switch on the blood lipid profile remain to be clarified. This is an important issue as TDF is known to have effects on both low- and high-density lipids. Therefore, our retrospective multi-center study aimed to evaluate the effects of switching from TDF to TAF on the lipid profile of patients with HBV infection. Samples were obtained prior to the switch from TDF to TAF and at 6\u201312 months after TAF initiation. In some cases, additional samples obtained pre- and post-TDF administration were available for analysis. Serum cholesterol levels, including oxidized-low-density lipoprotein (LDL) and non-high-density lipoprotein-cholesterol (HDL-c), and the rate of dyslipidemia, according to the NCEP-ATP III lipid risk classification, were analyzed. The data from 69 patients were analyzed, including 33 patients with pre- and post-TDF-initiation serum samples. Total cholesterol (T-chol), HDL-c, LDL-c, non-HDL-c, and oxidized LDL levels increased significantly after switching to TAF. With regard to sequential changes pre- to post-TAF, TDF was associated with significantly lower serum T-chol, HDL-c, and oxidized LDL-c levels, with T-chol, HDL-c, LDL-c, and oxidized LDL-c levels increasing significantly after the switch. The switch from TDF to TAF was also associated with an increase in the rate of dyslipidemia, from 33% to 39%, with an increase in the rate of severe dyslipidemia of 1.4% and 5.8%, based on T-chol and LDL-c levels. Of note, no cases of severe dyslipidemia were detected pre-TAF treatment. As oxidized LDL-c and non-HDL-c are strongly associated with atherosclerosis development, careful monitoring of lipid is needed after switching from TDF to TAF in this clinical population.<\/jats:p>","DOI":"10.1371\/journal.pone.0261760","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T18:28:04Z","timestamp":1642703284000},"page":"e0261760","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":38,"title":["Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B"],"prefix":"10.1371","volume":"17","author":[{"given":"Kazuharu","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0098-9106","authenticated-orcid":true,"given":"Goki","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Abiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Maehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kitagataya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Shigesawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kawagishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Sho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuteru","family":"Natsuizaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"issue":"24","key":"pone.0261760.ref001","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJM199712113372406","article-title":"Hepatitis B virus infection","volume":"337","author":"WM Lee","year":"1997","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0261760.ref002","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1111\/j.1440-1746.2011.06785.x","article-title":"Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C","volume":"26","author":"SR Walter","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"pone.0261760.ref003","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1128\/CMR.12.2.351","article-title":"Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection","volume":"12","author":"FJ Mahoney","year":"1999","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl S1","key":"pone.0261760.ref004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hepr.12269","article-title":"JSH Guidelines for the Management of Hepatitis B Virus Infection","volume":"44","author":"Drafting Committee for Hepatitis Management G, the Japan Society of H","year":"2014","journal-title":"Hepatol Res"},{"issue":"2","key":"pone.0261760.ref005","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"issue":"4","key":"pone.0261760.ref006","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"NA Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"8","key":"pone.0261760.ref007","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/hepr.13504","article-title":"Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update","volume":"50","author":"Drafting Committee for Hepatitis Management Guidelines tJSoH","year":"2020","journal-title":"Hepatol Res"},{"issue":"4","key":"pone.0261760.ref008","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"K Agarwal","year":"2018","journal-title":"J Hepatol"},{"issue":"9","key":"pone.0261760.ref009","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/apt.14945","article-title":"Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment","volume":"48","author":"GL Wong","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"pone.0261760.ref010","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/hepr.13399","article-title":"Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysis","volume":"49","author":"K Suzuki","year":"2019","journal-title":"Hepatol Res"},{"issue":"9","key":"pone.0261760.ref011","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00535-020-01698-4","article-title":"An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia","volume":"55","author":"MR Charlton","year":"2020","journal-title":"J Gastroenterol"},{"issue":"2","key":"pone.0261760.ref012","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/gutjnl-2016-312653","article-title":"Induction of IFN-lambda3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection","volume":"67","author":"K Murata","year":"2018","journal-title":"Gut"},{"issue":"6","key":"pone.0261760.ref013","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/apt.14218","article-title":"Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers","volume":"46","author":"AA Shaheen","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"pone.0261760.ref014","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/cid\/civ296","article-title":"The lipid-lowering effect of tenofovir\/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial","volume":"61","author":"JR Santos","year":"2015","journal-title":"Clin Infect Dis"},{"key":"pone.0261760.ref015","article-title":"Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36\/PPAR-alpha activation in hepatitis B virus infection","author":"K Suzuki","year":"2020","journal-title":"J Gastroenterol"},{"key":"pone.0261760.ref016","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.2147\/DDDT.S274307","article-title":"The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile","volume":"14","author":"N Squillace","year":"2020","journal-title":"Drug Des Devel Ther"},{"issue":"23 Suppl 1","key":"pone.0261760.ref017","first-page":"III8","article-title":"HDL cholesterol and protective factors in atherosclerosis","volume":"109","author":"G Assmann","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"pone.0261760.ref018","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1161\/CIRCULATIONAHA.107.745174","article-title":"Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis","volume":"118","author":"Y Ishigaki","year":"2008","journal-title":"Circulation"},{"issue":"7709","key":"pone.0261760.ref019","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41586-018-0198-8","article-title":"Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice","volume":"558","author":"X Que","year":"2018","journal-title":"Nature"},{"issue":"1","key":"pone.0261760.ref020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00535-017-1353-y","article-title":"Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan","volume":"53","author":"G Suda","year":"2018","journal-title":"J Gastroenterol"},{"issue":"10","key":"pone.0261760.ref021","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1007\/s00535-017-1328-z","article-title":"Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy","volume":"52","author":"G Suda","year":"2017","journal-title":"J Gastroenterol"},{"issue":"7","key":"pone.0261760.ref022","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00535-019-01556-y","article-title":"Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection","volume":"54","author":"G Suda","year":"2019","journal-title":"J Gastroenterol"},{"issue":"1","key":"pone.0261760.ref023","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/jgh3.12209","article-title":"Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting","volume":"4","author":"T Sho","year":"2020","journal-title":"JGH Open"},{"issue":"8","key":"pone.0261760.ref024","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/hepr.13511","article-title":"Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria","volume":"50","author":"T Sho","year":"2020","journal-title":"Hepatol Res"},{"issue":"6","key":"pone.0261760.ref025","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/hepr.13499","article-title":"Analysis of the optimal psoas muscle mass index cut-off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people","volume":"50","author":"M Ohara","year":"2020","journal-title":"Hepatol Res"},{"issue":"5","key":"pone.0261760.ref026","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jhep.2017.04.008","article-title":"Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection","volume":"67","author":"N Kawagishi","year":"2017","journal-title":"J Hepatol"},{"issue":"19","key":"pone.0261760.ref027","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)","volume":"285","author":"Expert Panel on Detection E","year":"2001","journal-title":"JAMA"},{"issue":"1","key":"pone.0261760.ref028","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5551\/jat.11.6","article-title":"Non-HDL cholesterol as a measure of atherosclerotic risk","volume":"11","author":"CJ Packard","year":"2004","journal-title":"J Atheroscler Thromb"},{"issue":"3","key":"pone.0261760.ref029","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"M Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"pone.0261760.ref030","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2174\/1570162X18666200824101838","article-title":"Real-Life Impact on Lipid Profile of a Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected Patients","volume":"19","author":"J Lagoutte-Renosi","year":"2021","journal-title":"Curr HIV Res"},{"issue":"10","key":"pone.0261760.ref031","doi-asserted-by":"crossref","first-page":"ofz414","DOI":"10.1093\/ofid\/ofz414","article-title":"Changes in Body Mass Index and Atherosclerotic Disease Risk Score After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide","volume":"6","author":"JJ Schafer","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"14","key":"pone.0261760.ref032","first-page":"915","article-title":"Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity","volume":"320","author":"D Steinberg","year":"1989","journal-title":"N Engl J Med"},{"issue":"72","key":"pone.0261760.ref033","doi-asserted-by":"crossref","first-page":"re3","DOI":"10.1126\/scisignal.272re3","article-title":"CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior","volume":"2","author":"RL Silverstein","year":"2009","journal-title":"Sci Signal"},{"issue":"12","key":"pone.0261760.ref034","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.2337\/db07-0907","article-title":"Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity","volume":"56","author":"DP Koonen","year":"2007","journal-title":"Diabetes"},{"issue":"7","key":"pone.0261760.ref035","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1161\/ATVBAHA.107.161653","article-title":"Mouse CD36 has opposite effects on LDL and oxidized LDL metabolism in vivo","volume":"28","author":"V Luangrath","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"pone.0261760.ref036","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.M011981","article-title":"Scavenger receptor CD36 mediates uptake of high density lipoproteins in mice and by cultured cells","volume":"52","author":"M Brundert","year":"2011","journal-title":"J Lipid Res"},{"issue":"4","key":"pone.0261760.ref037","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1053\/j.gastro.2017.07.001","article-title":"Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study","volume":"153","author":"MW Yu","year":"2017","journal-title":"Gastroenterology"},{"issue":"4","key":"pone.0261760.ref038","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005387","article-title":"Association of Tenofovir Use With Risk of Incident Heart Failure in HIV-Infected Patients","volume":"6","author":"R Chen","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"14","key":"pone.0261760.ref039","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1097\/QAD.0b013e32833d2132","article-title":"Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness","volume":"24","author":"JA Delaney","year":"2010","journal-title":"AIDS"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0261760","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T01:52:28Z","timestamp":1700099548000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0261760"}},"subtitle":[],"editor":[{"given":"Isabelle","family":"Chemin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0261760","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,20]]}}}